In our cohort of non-diabetic NAFLD/NASH patients, we observed impaired GLP-1 secretion in response to oGTT with consequences for insulin, glucagon and glucose dynamics in comparison to a healthy control group. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.